| I-01 Noha Abdelgawad Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis Wednesday 10:00-11:30 |
| I-07 Mounier Almett Population Pharmacokinetic Modelling of Twice Daily 50mg Dolutegravir in Children with Tuberculosis and HIV during Rifampicin Co-administration Wednesday 10:00-11:30 |
| I-10 Adamiszak Arkadiusz Antibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis Wednesday 10:00-11:30 |
| I-13 Aurélie Barrail-Tran Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates Wednesday 10:00-11:30 |
| I-19 Sandra Berja Population PK analysis of chloroquine in a humanized mouse model of P.falciparum malaria Wednesday 10:00-11:30 |
| I-22 Jose Miguel Calderin Miranda Pharmacokinetic analysis of pyrazinamide in a South African population with tuberculosis meningitis and HIV Wednesday 10:00-11:30 |
| I-25 Anan Chanruang Population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB Wednesday 10:00-11:30 |
| I-26 Zhendong Chen Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain Wednesday 10:00-11:30 |
| I-32 Ivan Demin Population pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis Wednesday 10:00-11:30 |
| I-34 Thomas Duflot Modelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ? Wednesday 10:00-11:30 |
| I-39 Aneeq Farooq In vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate. Wednesday 10:00-11:30 |
| I-43 Wei Gao Population PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria Wednesday 10:00-11:30 |
| I-45 Kamunkhwala Gausi Bactericidal activity of pretomanid against drug-sensitive tuberculosis in the presence of rifamycins Wednesday 10:00-11:30 |
| I-54 Ibtihel Hammami Application of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy Wednesday 10:00-11:30 |
| I-55 Irene Hernández-Lozano Translational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections Wednesday 10:00-11:30 |
| I-62 Felix Jost Model-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design Wednesday 10:00-11:30 |
| I-63 Piotr Juszczak Modelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older Wednesday 10:00-11:30 |
| I-64 Allan Kengo Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Wednesday 10:00-11:30 |
| I-65 Charlotte Kern Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial Wednesday 10:00-11:30 |
| I-66 Dohoon Keum Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients Wednesday 10:00-11:30 |
| I-69 Simon Koele Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis Wednesday 10:00-11:30 |
| I-72 Yu-wei Lin Population pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg Wednesday 10:00-11:30 |
| I-92 Sebastian Wicha In vitro pharmacodynamic drug-drug interaction and translational evaluation of cabamiquine and pyronaridine as new antimalarial combination using P.falciparum field isolates Wednesday 10:00-11:30 |
| I-93 Marie Wijk Analysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis Wednesday 10:00-11:30 |
| I-94 Venkata Yellepeddi Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients Wednesday 10:00-11:30 |
| I-97 Yu-Jou Lin A pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment Wednesday 10:00-11:30 |
| IV-06 Lu Chen Posaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race Thursday 15:25-16:55 |
| IV-19 Ryuji Kubota Developing SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer Thursday 15:25-16:55 |
| IV-21 Minji Kwon Optimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches Thursday 15:25-16:55 |
| IV-24 Silvia Maria Lavezzi Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study Thursday 15:25-16:55 |
| IV-25 Albin Leding Population pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites Thursday 15:25-16:55 |
| IV-28 Giulia Lestini Population pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria Thursday 15:25-16:55 |
| IV-30 Letao Li Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role? Thursday 15:25-16:55 |
| IV-37 Wen Yao Mak Population pharmacokinetics and pharmacodynamics of eravacycline against pulmonary infections Thursday 15:25-16:55 |
| IV-41 Laurynas Mockeliunas Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Thursday 15:25-16:55 |
| IV-42 Felix Müller Identification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study. Thursday 15:25-16:55 |
| IV-45 Jacinta Nwogu Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites Thursday 15:25-16:55 |
| IV-46 Amaury O'Jeanson Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration? Thursday 15:25-16:55 |
| IV-51 Elena Pascual García Towards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth. Thursday 15:25-16:55 |
| IV-54 Anh Duc Pham Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa Thursday 15:25-16:55 |
| IV-57 Veshni Pillay-Fuentes Lorente Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites Thursday 15:25-16:55 |
| IV-58 Tim Preijers Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study Thursday 15:25-16:55 |
| IV-63 Juan Eduardo Resendiz Galvan Pharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis. Thursday 15:25-16:55 |
| IV-70 Louis Sandra Development of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies Thursday 15:25-16:55 |
| IV-72 Maria Sanz Codina Evaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling Thursday 15:25-16:55 |
| IV-73 Raphaël Saporta Translation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments Thursday 15:25-16:55 |
| IV-75 Sharon Sawe Population pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis. Thursday 15:25-16:55 |
| IV-77 Manna Semere Gebreyesus Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy Thursday 15:25-16:55 |
| IV-79 Budi Octasari Susanto Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations Thursday 15:25-16:55 |
| IV-84 Marinda van de Kreeke Interspecies scaling of host inflammatory response during infection Thursday 15:25-16:55 |
| IV-86 Wisse van Os Model-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections Thursday 15:25-16:55 |
| IV-88 Peter Velickovic Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets Thursday 15:25-16:55 |
| IV-89 Diego Vera A translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin Thursday 15:25-16:55 |
| IV-91 Thanakorn Vongjarudech Optimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis Thursday 15:25-16:55 |
